Q-omics provides the consensus-scored DEFA10P profile across patient tissues and cancer cell-line models. DEFA10P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, DEFA10P is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, DEFA10P RNA expression shows 9,184 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRP, and THYM as cancer lineages where DEFA10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFA10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFA10P survival associations across molecular data types. DEFA10P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFA10P RNA expression–survival associations across cancer types. High DEFA10P expression shows unfavorable associations in CESC, STAD, GBM, READ and LGG, but favorable associations in THYM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for DEFA10P RNA expression.
This table summarizes DEFA10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFA10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFA10P shows lower tumor expression in BRCA and HNSC and higher tumor expression in KIRP and LIHC. The KIRP box plot shows higher DEFA10P RNA expression in tumor versus normal tissue (log2 FC = +0.157, t-test p = .028).
This table shows molecular features associated with DEFA10P in patient tissues and cancer cell lines. In patient samples, DEFA10P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
